Scalable CNV Assays: Why Low-Pass WGS Outperforms Microarrays

When you're running hundreds to thousands of samples, CNV calling becomes an operations problem as much as a technical one: throughput, batch consistency, rerun rate, file standardization, and whether results can be reprocessed as methods evolve. Microarrays remain a proven approach for copy number profiling, but their workflow and cost structure can become operationally burdensome at cohort scale. Low-pass whole-genome sequencing (low-pass WGS; commonly ~0.1–1× depth in RUO programs) shifts the bottleneck toward a batchable "send → sequence → analyze" model with standardized deliverables and reprocessable artifacts.

In practice, the advantage is usually operational scalability and reprocessability, not universal per-event sensitivity across all sizes.

Key takeaways

• At cohort scale, "best CNV assay" often means "lowest operational friction": fewer bottlenecks, clearer QC gates, and fewer rerun triggers.
• Low-pass WGS can offer better operational elasticity by standardizing deliverables (FASTQ/BAM/segments/QC) and enabling compute reprocessing instead of wet-lab reruns.
• Callability is conditional: depth, bin size, caller choice, GC/mappability masking, and coverage uniformity can move the "callable range."
• Define deliverables + QC gates upfront to prevent hidden costs (reruns, hands-on time, batch drift monitoring overhead).
• If you need focal (small) event resolution or strict legacy comparability, arrays may still be the more pragmatic choice—depending on your study constraints.

1. The Buyer Problem: Scaling CNV to Hundreds or Thousands of Samples

1.1 Why arrays become operationally painful at scale

Microarrays can be excellent for CNV profiling, but at high sample volumes, several practical issues tend to dominate:

• Labor and scheduling overhead: hybridization and wash/scan steps add coordination complexity. Even with experienced staff, these manual stages create variability that's hard to eliminate across thousands of samples.
• Batch effects and rework risk: handling variation, scan settings, and reagent lot differences can manifest as batch artifacts that require re-normalization or reruns.
• Rigid content model: array intensity signals are tied to probe design. That's fine for stable questions, but less flexible if you expect to revisit the cohort with updated references, masks, or segmentation models.

If multiple stakeholders are aligning on definitions and caveats, a concise terminology refresh can reduce downstream miscommunication.
Need a quick refresher on CNV basics and key terminology? Start with this CNV definition guide.

1.2 What low-pass WGS changes (automation, throughput, data reuse potential)

Low-pass WGS reframes the platform decision from "which wet-lab assay" to "how standardized is your end-to-end pipeline":

• Automation-friendly batching: library prep and sequencing are inherently batch-oriented; scaling is often achieved by increasing batch size and run cadence rather than multiplying bespoke handling steps.
• Uniform deliverables: programs can define a consistent output package (FASTQ, aligned BAM/CRAM, bin-level coverage, segmented CNV calls, QC summaries) and enforce it across runs.
• Reprocessing instead of rerunning: you can re-run compute with improved callers, updated masks, or revised binning strategies—without repeating wet-lab steps (assuming upstream artifacts are preserved).

Low-pass WGS often provides better operational elasticity and standardized deliverables at cohort scale, assuming QC gates and reprocessing artifacts are defined upfront.

If you want to reduce avoidable reruns before the first batch ships, it helps to standardize sample acceptance criteria and submission metadata early using a consistent SOP such as CD Genomics' sample submission guidelines.

Figure 1. Side-by-side operational workflow: microarray vs low-pass WGS.

Microarray workflows typically include more manual, stepwise handling (hybridization and wash/scan steps leading to probe-intensity outputs), while low-pass WGS often streamlines into batchable "Sample QC → Library Prep → Sequencing → CNV Calling" with standardized downstream artifacts.
How to use this figure: identify where your program's bottleneck occurs (manual handling vs computational standardization) and mark the most likely rerun triggers (late QC failures, batch drift, or unstable segmentation).

1.3 When you should still choose arrays (edge cases)

Low-pass WGS is not automatically the best fit for every RUO program. Arrays may still be preferred when:

• You need a probe-defined content model aligned to legacy datasets or fixed loci strategies.
• Your program's primary success metric is high confidence in smaller/focal events relative to what your low-pass depth and binning can support economically.
• You already have an optimized, stable array facility with low operational friction and predictable batch normalization.
• Sample constraints (e.g., challenging inputs) make your established array pipeline more robust than sequencing library prep in your setting.

For teams committed to arrays, outsourcing can still improve throughput if you standardize QC and deliverables; see CD Genomics' Microarray Services for operational options.

2. Head-to-Head: What You Get From Each Platform

2.1 Resolution: probe density vs binning depth (what "callable" means)

A common pitfall is equating "resolution" with "best" without defining callability for your study.

• Microarray callability depends on probe density and probe distribution; sensitivity varies by genome region and probe design.
• Low-pass WGS callability depends on depth, coverage uniformity, and the binning/normalization strategy. At low depth, you typically trade focal resolution for stability in large-event detection and cohort consistency.

A practical operator's definition is: callable CNV size is the event-size range where your platform delivers reliable segmentation with acceptable false-positive/false-negative trade-offs under your QC gates.

Boundary conditions that affect callability

Callability is not a fixed property of "arrays vs low-pass WGS"—it shifts with design choices and genome context. Key boundary conditions include:

• Genome size and complexity: large genomes or repeat-rich genomes increase mapping ambiguity and can raise the noise floor.
• Bin size strategy: larger bins stabilize signals at low depth but blur focal boundaries; smaller bins increase resolution but amplify noise sensitivity.
• Caller and segmentation model: different callers (and parameterization) behave differently on low-pass data; cohort-aware normalization can be decisive.
• GC and mappability masking: effective bias correction and excluding low-mappability regions often improves stability but changes what is callable.
• Coverage uniformity: uneven coverage and library complexity artifacts can drive unstable segmentation even if total read count looks adequate.

Mandatory caveat: results are study-specific and RUO-only; you should validate assumptions on representative samples and a subset pilot before scaling.

2.2 Sensitivity by event size (large chromosomal vs focal CNVs)

At cohort scale, many RUO programs prioritize reliable detection of larger events (multi-megabase deletions/duplications, arm-level changes), because:

• Signal-to-noise is stronger and QC is easier to standardize.
• Batch drift detection is simpler with stable large-scale signals.
• Downstream cohort analytics are less fragile.

Low-pass WGS often performs well in this regime, but it's still dependent on depth, binning, and caller choices. Arrays can also perform well, though performance may vary by region depending on probe distribution and GC/repeat context.

Figure 2. Conceptual relationship between event size and detection confidence for microarrays vs low-pass WGS.

Detection confidence often improves with event size; the highlighted "Callable Range" depicts where outputs are typically most stable for cohort-scale CNV profiling under common QC constraints.
Disclaimer: Callable ranges shift with depth, bin size, and caller choice; this figure is conceptual.

2.3 Data types delivered: raw files, aligned BAM, segment tables, QC metrics

For procurement and pipeline integration, deliverables can matter as much as detection performance. A cohort-ready low-pass WGS package typically includes:

• Raw data: FASTQ
• Aligned data: BAM/CRAM (+ index)
• Coverage artifacts: bin-level depth tables, normalization/bias summaries, masks used (GC/repeats/mappability)
• CNV calls: segmentation table (coordinates, log2 ratios or CN estimates, confidence fields)
• QC summary: per-sample + per-batch QC flags and rerun recommendations

Programs that plan to operationalize reprocessing often align these artifacts with a standardized analysis handoff, supported by Bioinformatics Services and downstream Genomic Data Analysis.

3. Cost and Timeline Drivers

3.1 Main cost levers: sample count, genome size, depth, analysis scope

In high-throughput programs, the "cost of CNV analysis" is driven by more than per-sample consumables. The main levers include:

• 1. Depth choice (~0.1× to ~1×): Higher depth can improve focal callability and reduce noise, but increases run consumption.
• 2. Genome size and sequence complexity: Complex genomes increase mapping uncertainty and can require stronger masking and more conservative thresholds.
• 3. Batching and utilization: Underfilled runs can increase cost per sample; inconsistent batching can increase drift monitoring and rework.
• 4. Analysis scope and reporting: There's a major scope difference between "deliver a segment table" and "deliver standardized QC gates + filtering + audit artifacts + cohort summaries."

Practical depth-to-goal mapping (experience-based starting point; not a guarantee)

Starting ranges must be tuned to genome, library prep, and cohort baseline; depends on caller behavior and your minimum event-size goal.

Figure 3. Cost driver iceberg: visible costs vs hidden operational costs.

Visible costs include direct consumables and run consumption, while hidden costs often dominate total program spend at cohort scale—especially rerun rate, hands-on time, and batch drift monitoring overhead. Treat these as measurable operational KPIs (e.g., rerun %, minutes of hands-on work per sample, drift flags per batch) when comparing platforms or vendors.

If you need a single accountable workflow from sequencing operations through analysis artifacts, CD Genomics offers sequencing-centered pipelines via CNV Sequencing and broader Next-Generation Sequencing.

3.2 Timeline levers: batching, automation, rework triggers

RUO turnaround time is often limited by queueing and rework, not just instrument runtime.

• Batching strategy: larger batches reduce overhead per batch but can increase queue time; smaller batches increase agility but may reduce utilization.
• Automation and SOP maturity: reduces hands-on time and lowers variability-driven rerun triggers.
• Stage gating: prevents "silent failures" discovered only after segmentation.

If you expect frequent reorder cycles, consolidating SOPs and acceptance criteria into your purchasing workflow can reduce project friction at scale.

3.3 ROI logic: fewer bottlenecks + standardized outputs

ROI in cohort-scale CNV profiling often comes from:

• Lower bottleneck pressure (less manual work per sample)
• Lower rerun rates (better gating and acceptance criteria)
• Higher reusability (reprocessing compute instead of repeating wet-lab)
• Standardized output schemas (easier integration into downstream systems)

4. Data Reusability: Why Sequencing is Future-Proof

4.1 Re-analysis with improved callers or updated references

One operational benefit of sequencing-centered programs is the ability to re-run compute as methods improve:

• Updated reference builds and contig handling
• Updated blacklists/masks (repeats, low mappability)
• Improved GC correction and cohort-aware normalization
• Alternative callers or segmentation models tuned to your genome and cohort

This becomes increasingly valuable for multi-quarter cohorts where analytic methods evolve.

4.2 Compatibility with broader variant discovery strategies (research databases)

Even if your immediate goal is CNV profiling, sequencing-aligned artifacts can integrate more naturally with future research analyses and cohort expansion. For broad discovery roadmaps, many teams pair WGS-centric deliverables with downstream methods such as Variant Calling and population-scale analyses like Genome-Wide Association Study (GWAS) when appropriate to RUO study design.

4.3 Integrating CNV with other omics (optional)

If your program anticipates multi-layer data integration later, designing your CNV workflow around consistent sample identity, batch metadata, and QC traceability can reduce future harmonization work. For organizations planning integrated programs, see CD Genomics' Multi-Omics offerings as a roadmap reference.

5. What to Ask a Vendor (Ops/Procurement Checklist)

5.1 Required deliverables (what you should request explicitly)

Ask vendors to provide a written deliverables specification—file list, field schema, QC gates, and rerun policy—so your cohort remains consistent across batches.

At minimum, request:

• FASTQ
• BAM/CRAM (+ index)
• bin-level coverage artifacts + masks used
• segmentation/CNV calls + confidence fields
• per-sample and per-batch QC summaries

Many programs reduce downstream integration time by defining an "output contract" that vendors must meet.

Deliverables schema (example fields)

Below is an example schema you can adapt (fields may differ by caller; this is a template):

If you want a single accountable partner to deliver both wet-lab outputs and analysis artifacts under one SOP, the pairing of CNV Sequencing with Genomic Data Analysis is a common operational pattern.

5.2 Batch consistency and QC gating (the "scale insurance policy")

For thousands of samples, the biggest risk reducer is explicit, enforced QC gating—both per sample and across batches.

Ask:

• What are the pass/fail thresholds at each gate?
• How are outliers detected across historical batches?
• What triggers reruns, and at what stage do reruns occur?
• Do you provide batch drift monitoring artifacts and escalation rules?

For a technical deep dive into CNV calling with cn.mops and pipeline QC for low-pass data, see this bioinformatics guide.

5.3 Handling low-quality samples and repeats-rich genomes

This is where cohort programs often lose money: low-quality inputs discovered too late, or genomes where mapping uncertainty inflates noise.

Ask vendors:

• What are sample acceptance criteria (concentration, total input mass, degradation indicators)?
• How do you handle repeat-rich regions (mappability masking, excluded bins)?
• What are your "fail" definitions—stop early vs proceed with "limited interpretability" labeling?
• What metadata must accompany each sample to ensure consistent processing?

Procurement packet mini-template (copy/paste)

Use the template below as a lightweight procurement packet you can reuse across vendors.

A) Mandatory deliverables (file-level checklist)

• 1. FASTQ files (paired-end if applicable) + checksum
• 2. BAM/CRAM + index + reference build identifier
• 3. Bin-level coverage table (bin size stated)
• 4. Mask/blacklist files used (GC/mappability/repeats)
• 5. Segment/CNV call table with required fields (chr/start/end/log2 or CN/confidence)
• 6. Per-sample QC summary (Gate 1–4 pass/fail flags)
• 7. Batch QC summary (drift/outliers + corrective actions)
• 8. Software versions (aligner/caller) + parameter snapshot

B) Example output package request (to compare vendors fairly)

9. "Provide a complete output package (all files above) for 3 representative samples: one typical-pass, one marginal-pass, one fail."
10. "Include an explanation of why each sample passed/failed and what rerun action is recommended."

C) Rerun policy + drift monitoring questions

11. "At which QC gate do you stop processing a sample (and why)?"
12. "What triggers a rerun vs a 'limited interpretability' label?"
13. "How do you quantify batch drift and what thresholds cause intervention?"
14. "Do you reprocess historical batches if the pipeline changes (caller/mask/binning)?"
15. "What is your expected rerun rate range in similar cohorts, and how do you manage it operationally?"
16. "How do you ensure file schema consistency across quarters and across staff/instruments?"

QC & Troubleshooting (Symptoms → Likely Causes → Practical Fixes)

Starting ranges must be tuned to genome, library prep, and cohort baseline.

QC gating metrics table (action-oriented starting points; tune to your program)

Below is an operational QC table emphasizing Gate 3 (sequencing/alignment) and Gate 4 (coverage/segmentation) with explicit actions. These are starting points—your cohort baseline may justify different thresholds.

Common issues in cohort-scale low-pass WGS CNV calling

1) High duplication rate in a subset of batches

• Likely causes: low input DNA, over-amplification, inconsistent library prep
• Fixes: tighten input acceptance criteria; standardize PCR cycles; track library complexity trends; intervene if duplication drift appears batch-wide

2) Mapping rate drops across a sample subset

• Likely causes: contamination, poor DNA quality, reference mismatch, high repeat content
• Fixes: enforce pre-flight QC; confirm reference build; apply mappability masks; adjust binning; label outputs as limited interpretability when appropriate

3) Excessive segmentation (too many small segments)

• Likely causes: noisy coverage, GC bias, batch effects, insufficient normalization
• Fixes: strengthen GC correction; exclude unstable bins; increase minimum segment size; switch to cohort-aware normalization; reprocess with tuned caller parameters

4) Batch-to-batch drift in noise metrics

• Likely causes: reagent lot changes, instrument drift, inconsistent handling
• Fixes: lock SOPs; monitor batch QC dashboards; enforce corrective actions; preserve reprocessing artifacts so drift corrections can be applied consistently over time

Decision Framework

Use this framework to select a platform based on RUO cohort objectives rather than single-sample "best-case" performance.

Arrays vs low-pass WGS (operator-centric comparison)

When low-pass WGS is often the better choice

• You need cohort-scale CNV profiling with stable batching and standardized artifacts.
• You value the ability to reprocess outputs as methods evolve, without repeating wet-lab steps.
• You can define QC gates and file schemas upfront and enforce them across batches.

When arrays can still be the better choice

• Your primary requirement is strict legacy comparability to existing array datasets.
• Your target CNV class is highly focal and you have a probe design that supports that goal.
• You already have a stable, optimized array operation with minimal rework.

FAQ

• 1) What depth counts as "low-pass WGS" for CNV profiling?
  In RUO programs, low-pass commonly refers to sub-1× WGS. The practical depth depends on event-size goals, genome complexity, and acceptable noise. Many teams confirm depth decisions with a pilot batch and then lock the SOP.
• 2) Is low-pass WGS suitable for very small, gene-level CNVs?
  It can be, but depends on depth, binning, and caller behavior. If your primary objective is focal event confidence, you may need higher depth, different strategies, or arrays designed for that resolution.
• 3) What deliverables should procurement require?
  At minimum: FASTQ, BAM/CRAM, coverage/bias artifacts and masks used, a segment table with required fields, and a QC summary with pass/fail flags and rerun recommendations.
• 4) How do we keep reruns from driving total cost?
  Define QC gates and rerun triggers upfront, ensure pre-flight sample acceptance criteria are enforced, and require batch drift monitoring artifacts. Most "hidden cost" comes from late discovery of preventable failures.
• 5) If we start with arrays, can we switch later?
  Yes, but platform switching creates integration work (schema differences, baseline shifts, and re-benchmarking). If your multi-quarter plan emphasizes reusability, sequencing-aligned artifacts can reduce migration friction later.
• 6) Do we need in-house bioinformatics for low-pass CNV calling?
  Not necessarily, but you do need a clear output contract: caller approach, QC thresholds, deliverable formats, and audit artifacts—otherwise batch-to-batch variability becomes difficult to manage.
• 7) How should we compare vendors fairly?
  Send the same deliverables schema and procurement packet template to every vendor, and request example output packages for representative samples (pass/marginal/fail) to compare consistency and clarity.
• 8) What's the fastest way to reduce friction before the first batch ships?
  Standardize sample metadata requirements, acceptance criteria, file schemas, QC gates, and rerun policy. If you're outsourcing, keep ordering and documentation centralized so nothing changes quietly mid-cohort.

References:

1. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Research (2007). DOI: 10.1101/gr.6861907
2. Klambauer G, Schwarzbauer K, Mayr A, et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Research (2012). DOI: 10.1093/nar/gks003
3. Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. Nature Reviews Genetics (2009). DOI: 10.1038/nrg2593
4. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Computational Biology (2016). DOI: 10.1371/journal.pcbi.1004873
5. CNVkit documentation (software user guide): Bias corrections for GC, repeats, and target density. https://cnvkit.readthedocs.io/en/stable/ (Accessed 2026-02-26)